Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

13/11/2024 07:01

Nov 13 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Sep 30, 2024        Sep 30, 2023     Dec 31, 2024 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              81 mln              602 mln                    
                   (-86.5 pct)         (+24.3 pct)                  
  Operating       loss 892 mln        loss 787 mln                  
  Pretax          loss 892 mln        loss 784 mln                  
  Net             loss 871 mln        loss 768 mln                  
  EPS Basic       loss 4.53 yen       loss 4.57 yen                 
  EPS Diluted     loss 4.53 yen       loss 4.57 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div              NIL                 NIL                      
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T